ResMed Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from ResMed Inc.'s yearly results (2023–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 12.6 times. Higher than 95% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
$126Over the last 3 years, every $100 of reported profit came with $126 of operating cash.
Lower than 67% of Healthcare companies in United States.
Self-Funding Ratio
12.6×Over the last 3 years its own operating cash covered its investment spending (capex) 12.6 times.
Higher than 95% of Healthcare companies in United States.
Cash Locked Ratio
$28For every $100 of sales, $28 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $34 tied up three years earlier.
More money tied up than 61% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$44Sales grew 34% in 3 years; of every extra $100 of sales, $44 became extra profit.
Higher than 66% of Healthcare companies in United States.
Asset Productivity Ratio
+34% / +33%In 3 years sales changed by +34% while total assets changed by +33%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
6.9×Debt due within a year is covered 6.9 times by its yearly operating cash.
Higher than 82% of Healthcare companies in United States.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Lower than 64% of Healthcare companies in United States.
Tangible Assets Ratio
62%Of every $100 the company owns, $62 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 67% of Healthcare companies in United States.
Tangible Net Worth Ratio
49%Of every $100 of net worth, $49 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 53% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
ResMed Inc. owes $0.27 for every $1 it owns. Net profit rose 9% in the year to Jun 2026, and grew 19% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Jun 2026.
P/E ratio
24.2Investors pay $24.2 for every $1 of ResMed Inc.'s yearly profit, lower than 55% of Healthcare companies in United States.
P/B ratio
5.40The share price is 5.40 times ResMed Inc.'s book value per share, higher than 74% of Healthcare companies in United States.
Market cap
$35.6 BThe total market value of all of ResMed Inc.'s shares at today's price (share price × number of shares), larger than 95% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$6.6 BWhat ResMed Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$46.82Net worth divided by the number of shares. The share price of $252.86 is 5.4 times this, which is the P/B above.
Return on equity (ROE)
24.3%ResMed Inc. earned 24.3% on its shareholders' money over the last year, higher than 92% of Healthcare companies in United States.
Owes vs Owns
0.27×ResMed Inc. owes $0.27 for every $1 it owns (low), lower than 65% of Healthcare companies in United States.
Dividend yield
1.04%ResMed Inc. pays 1.04% of its share price as dividends a year, lower than 52% of dividend-paying Healthcare companies in United States.
Revenue growth
+10%Revenue rose 10% in the year to Jun 2026, and grew 10% a year on average over 3 years.
Profit growth
+9%Net profit rose 9% in the year to Jun 2026, and grew 19% a year on average over 3 years.
Profit margin
26.9%ResMed Inc. keeps $27 of every $100 of revenue as net profit.
Cash quality
1.2×Cash from ResMed Inc.'s business was 1.2× its reported profit in the year to Jun 2026 — its profit turned into cash.
Cash vs debt
Net cashResMed Inc. held $643 M more cash than debt (net cash) at Jun 2026.
Questions
What is ResMed Inc.'s P/E ratio?
Investors pay $24.2 for every $1 of ResMed Inc.'s yearly profit, lower than 55% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For ResMed Inc.: $35.6 B ÷ $6.6 B (30 Jun 2026) = 5.4.
What is ResMed Inc.'s return on equity?
ResMed Inc. earned 24.3% on its shareholders' money over the last year, higher than 92% of Healthcare companies in United States.
How much does ResMed Inc. owe compared with what it owns?
ResMed Inc. owes $0.27 for every $1 it owns (low), lower than 65% of Healthcare companies in United States.
Does ResMed Inc. pay a dividend?
Yes. ResMed Inc. pays 1.04% of its share price as dividends a year, lower than 52% of dividend-paying Healthcare companies in United States.
Is ResMed Inc.'s revenue growing?
Revenue rose 10% in the year to Jun 2026, and grew 10% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.